Hepatitis C testing in drug users using the dried blood spot test and the uptake of an innovative self-administered DBS test

Addictive Disorders and their Treatment

Volumn 12, Issue 1, 2013, Pages 40-49

  Abou Saleh, Mohammed T ^a   Rice, Philip ^a   Foley, Suzanne ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

dried blood spot test; drug use; hepatitis C; injecting; nonstatutory; pathways to care; prison; self testing; treatment

Indexed keywords

ARTICLE; DRIED BLOOD SPOT TESTING; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRISON; RESPONSIBILITY; SELF CARE;

EID: 84874401517     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e318253c465     Document Type: Article

References (17)

1. Health Protection Agency. Hepatitis C in the UK London: Health Protection Agency, Colindale, London: UK; 2011. Available at: http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb-C/130996 9907625.
2. Abou-Saleh M, Davis P, Rice P, et al. The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduct J. 2008;31:25.
3. Abou-Saleh MT, Foley S. Prevalence and incidence of hepatitis c in drug users: a review. Addict Disord Treat. 2008;7:190-198.
4. National Institute of Clinical Excellence. "Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C" [NICE technology appraisal guidance 200 (TA200)]. Available at: www.nice.org.uk/guidance/TA200; 2006.
5. Department of Health. Department of Health Hepatitis C Action Plan for England. London: Department of Health; 2004.
6. Hickman M, McDonald T, Judd A, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15: 250-254. (Pubitemid 351326904)
7. Hope VD, Hickman M, Ngui SL, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 2011;18: 262-270.
8. Rice PS, Ang L, Shin GY, et al. The diagnostic utility of dried blood spot testing for hepatitis C infection. Gut. 2003;52:A107.
9. Judd A, Parry J, Hickman M, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol. 2003;71:49-55. (Pubitemid 37121912)
10. Susi AG. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338-343.
11. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study.BMJ. 2005;330:24-25. (Pubitemid 40070473)
12. CraineN,Walker AM, Williamson S, et al.Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Commun Dis Public Health. 2004;7:216-219.
13. Judd A, Hutchinson S, Wadd S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J ViralHepat. 2005;12:655-662. (Pubitemid 41532498)
14. National Treatment Agency/Department of Health. Models of care: a framework for drug misuse treatment. London: UK; 2002 Available at: http://www. nta.nhs.uk/publications/mocpart2/chapter1-1.htm.
15. Skipper C, Guy JM, Parkes J, et al. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003;52:1500-1504. (Pubitemid 37176732)
16. Kirwan P, Evans B, Brant LSentinel Surveillance of Hepatitis Testing Study Group. Hepatitis C and B testing in English prisons is low but increasing. J Public Health (Oxf). 2011;33:197-204.
17. Tait JM, McIntyre PG, McLeod S, et al. The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. J Viral Hepat. 2010;17:698-704.